Filter by Topic
In 1984, human genetics and reproduction researcher and physician Joseph D. Schulman founded the Genetics and IVF Institute, an international organization that provides infertility treatment and genetic services to patients. IVF stands for in vitro fertilization, an infertility treatment in which a female egg is fertilized by male sperm outside of the female body. GIVF is headquartered in Fairfax, Virginia, in association with Inova Health System, formerly called the Fairfax Hospital Association, one of the largest regional hospital systems in the United States.
In 1991, the
United Kingdom established the Human Fertilisation and Embryology
Authority (HFEA) as a response to technologies that used human embryos.
The HFEA is a regulatory power of the Health and Social Services
Department in London, UK, that oversees the implementation of
reproductive technologies and the use of embryos in research within the
United Kingdom. It establishes protocols by which researchers may use
human embryos, develops legislation on how human embryos are stored and
Johns Hopkins Medical Center, located in Baltimore, Maryland, opened in 1889; its associated medical school opened four years later. Today the hospital, a leading research center, contains many departments, including a fertility center that is renowned for taking on difficult cases that have been rejected by other fertility clinics. The fertility center was founded by physician Georgeanna Seegar Jones in 1939 as the Division of Reproductive Endocrinology in the gynecology department. The division expanded once formal training in reproductive endocrinology began in 1973.
In 1971, a group of researchers founded the Monash IVF Research Program with the mission to discover how in vitro fertilization, or IVF, techniques could become a treatment for infertility in both men and women. The program included researcher Carl Wood and colleagues John Leeton, Alex Lopata, Alan Trounson, and Ian Johnston at the Queen Victoria Medical Center and Royal Women’s Hospital in Melbourne, Australia. Since the program’s establishment in 1971, the Monash IVF Research Program has helped to develop and implement many IVF technologies still used in clinical practice as of 2020.
In 2015, Revive & Restore launched the Woolly Mammoth Revival Project with a goal of engineering a creature with genes from the woolly mammoth and introducing it back into the tundra to combat climate change. Revive & Restore is a nonprofit in California that uses genome editing technologies to enhance conservation efforts in sometimes controversial ways.
In the early twentieth century, scientists and agriculturalists collected plants in greenhouses, botanical gardens, and fields. Seed collection efforts in the twentieth century coincided with the professionalization of plant breeding. When scientists became concerned over the loss of plant genetic diversity due to the expansion of a few agricultural crops around mid-century, countries and organizations created seed banks for long-term seed storage.
Advanced Cell Technology, Inc. (ACT) is a biotechnology company that uses stem cell technology to develop novel therapies in the field of regenerative medicine. Formed in 1994, ACT grew from a small agricultural cloning research facility located in Worcester, Massachusetts, into a multi-locational corporation involved in using both human embryonic stem cells (hESC) and human adult stem cells as well as animal cells for therapeutic innovations.
The Stazione Zoologica Anton Dohrn (Anton Dohrn Zoological Station) is a public research institute focusing on biology and biodiversity. Hereafter called the Station, it was founded in Naples, Italy, in 1872 by Anton Dohrn. The type of research conducted at the Station has varied since it was created, though initial research focused on embryology. At the turn of the twentieth century, researchers at the Station established the sea urchin (Echinoidea) as a model organism for embryological research.